Patient P-01410
Therapy response
Improving
Tolerance
Deteriorating
GI state
Unstable
Inflammatory state
Unstable
Nutritional resilience
Unstable
Discontinuation risk
74%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S14
- Day 46 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 52 GI-04 recommended — GI Support Protocol GI-04
- Day 53 Patient accepted — Started GI-04 in the companion
- Day 61 No meaningful change — GI Support Protocol GI-04
What changed?
Trajectory began diverging from predicted response on Day 46.
Primary contributors, last 14 days
- Toxicity+13
- Nutritional resilience-6
- Inflammatory activity+4
- GI instability-3
What helped?
- GI Support Protocol GI-04Day 52Result: no meaningful change
LIFE OS recommendation
Dietary Support Protocol NP-02
61%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 66% showed improvement
- median effect visible after 10 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Inflammatory signalling ↑65
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 61
- WearableHRV 32 ms, trending down
- Mucosal barrier integrity ↓60
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 60 and rising
- WearableSleep 4.9 h, below personal baseline
- Butyrate / short-chain fatty acid production ↓55
- MicrobiomeButyrate capacity 32/100
- Daily logFibre intake low in recent food logs
- Autonomic recovery ↓40
- Wearable2,120 steps/day
- WearableShort sleep window
- Drug metabolism and exposure ↑20
- BloodToxicity index 54
DNA
Fictional pharmacogenomic panel
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Intermediate metabolizerExpected exposure
Microbiome
Shannon diversity 2.7 · butyrate capacity 32/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisNormal
- Bifidobacterium longumNormal
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 32 ms
- Sleep
- 5.5 h
- Steps
- 3,392
- Resting HR
- 71 bpm
Daily log: GI score 60, nutritional resilience 32, adherence 49.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.